Our results regarding AP2B1 and APP suggest that the early stages of the lysosomal pathway are specifically altered in the FTLD-linked disorders (and potentially particularly the primary tauopathies) when compared to those disorders with underlying AD pathology. This evidence concerns the gene APP and tauopathy.